(UroToday.com) Dr. Kelly Stratton gave a presentation at the 2020 Society of Urologic Oncology (SUO) Annual Virtual Meeting on peri-operative therapy for muscle-invasive bladder cancer (MIBC). He began his talk by demonstrating that the outcomes after radical cystectomy differ significantly according to the pathological results of cystectomy (Figure 1).1 Due to the fact that in some patients, radical cystectomy might not be enough, neoadjuvant chemotherapy (NAC) has been added as a standard of care. Based on level one evidence,2 NAC showed an overall survival benefit of 14% at five years when compared to cystectomy alone (Figure 2).